HK Stock Market Move | CSTONE PHARMA-B(02616) rose by over 6% again, and Sugliv monoclonal antibody received ESMO guidelines recommending first-line treatment for dual-indication non-small cell lung cancer.

CSTONE PHARMA-B(02616) rose by over 6%, as of press time, up 6.35% to HKD 2.68, with a turnover of HKD 3.4653 million. On the news front, CStone Pharmaceuticals announced yesterday that its heavyweight product Sugreligant monoclonal antibody (Teligent Dilys) has been included in the "ESMO NonOncogene-Addicted Metastatic Non-Small-Cell Lung Cancer (NSCLC) Living Guideline", and has become a first-line treatment recommended for both squamous and non-squamous non-small cell lung cancer (squamous NSCLC and non-squamous NSCLS) with high clinical benefits. Currently, sugreligant monoclonal antibody has been approved for first-line treatment of advanced non-small cell lung cancer in China, the European Union, and the United Kingdom. After successfully expanding into dozens of countries in Switzerland and Central and Eastern Europe, the Middle East and Africa, and Latin America and achieving commercial cooperation, the company is actively promoting strategic commercial cooperation in Western Europe, Southeast Asia, and Canada, as well as the overseas registration and listing process for sugreligant monoclonal antibody in other indications.